Blockchain Registration Transaction Record

Soligenix's HyBryte Shows Promising Results in Treating Rare Skin Cancer

Soligenix (NASDAQ: SNGX), a biopharmaceutical company, reveals promising results for its lead candidate, HyBryte, in treating rare skin cancer. With a 75% response rate in clinical trials, HyBryte shows potential as a groundbreaking therapy for cutaneous T-cell lymphoma.

Soligenix's HyBryte Shows Promising Results in Treating Rare Skin Cancer

This news matters as it highlights the potential breakthrough in treating cutaneous T-cell lymphoma, a rare and challenging form of skin cancer. The success of HyBryte, with its high response rate in clinical trials, offers hope to patients and showcases the innovative approach of Soligenix in addressing unmet medical needs.

BlockchainDetails
Contract Address0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71
Transaction ID0xc43b55efefdbdbe0a1991d59e324d4354bd8b5d931e6bbb36218843522ff61c5
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprintovalF0X8-94c478276878e3cfaf19ccc6333ecd45